Federal Register / Vol. 74, No. 136 / Friday, July 17, 2009 / Notices 34767 

with an affinity for CD47 for the 

preservation or resuscitation of organs 

and tissues for transplantation’’; (2) ‘‘the 

use of antibodies including humanized 

antibodies reacting with CD47 or related 

antigens, precursors, or molecules, and 

isolated and/or recombinant fragments, 

and conjugates with an affinity for CD47 

for treating or preventing vascular 

diseases, including but not limited to, 

pulmonary hypertension, sickle cell 

disease, myocardial infarction, stroke, 

and tissue ischemia resulting from 

trauma and surgical procedures’’; (3) 

‘‘the use of antisense oligonucleotides or 

RNA formulations of stabilized 

composition to reduce expression of 

CD47 for treating wounds and/or burns 

and for use in reconstructive surgery’’; 

and (4) ‘‘use of small molecules 

antagonists of CD47 for treating or 

preventing vascular diseases including, 

but not limited to, thrombosis, 

hypertension, peripheral artery disease, 

renal artery disease, and ischemia 

resulting from atherosclerosis’’ to 

Vasculox, Inc., having an office in at 

least St. Louis, Missouri, U.S.A. The 

patent rights in these inventions have 

been assigned to the United States of 

America. 

DATES: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before 

September 15, 2009 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, comments, 

and other materials relating to the 

contemplated exclusive license should 

be directed to: Charlene A. Sydnor, 

Ph.D., Licensing and Patenting Manager, 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, MD 

20852–3804; Telephone: (301) 435– 

4689; Facsimile: (301) 402–0220; E-mail: 

sydnorc@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: Nitric 

Oxide (NO) plays an important role as 

a major intrinsic vasodilator, and 

increases blood flow to tissues and 

organs. Disruption of this process leads 

to peripheral vascular disease, ischemic 

heart disease, stroke, diabetes and many 

more significant diseases. The inventors 

have discovered that the matrix protein 

thrombospondin1 (TSP1) blocks the 

beneficial effects of NO, and prevents it 

from dilating blood vessels and 

increasing blood flow to organs and 

tissues. Additionally, they discovered 

that this regulation requires TSP1 

interaction with its cell receptor, CD47. 

Relief of this inhibition in genetically 

altered mice lacking either TSP1 or 

CD47 results in dramatically improved 

blood flow and increased tissue 

oxygenation. Further, by using reagents 

such as monoclonal antibodies and 

peptides that block TSP1–CD47 

interaction, or agents such as antisense 

oligonucleotides or morpholinos that 

reduce the level of CD47 or TSP1, blood 

flow can dramatically increase to 

ischemic tissues in vivo. Inhibition of 

TSP1 signaling at the level of CD47 

expression and/or activation 

significantly improves the survival of 

tissue in an ischemic environment. 

The prospective exclusive license will 

be royalty bearing and will comply with 

the terms and conditions of 35 U.S.C. 

209 and 37 CFR part 404.7. The 

prospective exclusive license may be 

granted unless within sixty (60) days 

from the date of this published notice, 

the NIH receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404.7. 

Applications for a license in the field 

of use filed in response to this notice 

will be treated as objections to the grant 

of the contemplated exclusive license. 

Comments and objections submitted to 

this notice will not be made available 

for public inspection and, to the extent 

permitted by law, will not be released 

under the Freedom of Information Act, 

5 U.S.C. 552. 

Dated: July 10, 2009. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E9–17038 Filed 7–16–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Section 330A(e) of the Public Health 

Service Act, as Amended (42 U.S.C. 

254c(e)) and Section 317(k)(2) of the 

Public Health Service Act, as Amended 

(42 U.S.C. 247b(k)(2)) 

AGENCY: Health Resources and Services 

Administration, HHS. 

ACTION: Notice of Single Source Grant 

Award to Lincoln County Health 

Department in Libby, MT. 

SUMMARY: The Health Resources and 

Services Administration (HRSA) is 

issuing a new single source award 

through the Rural Health Care Services 

Outreach Grant Program and the Centers 

for Disease Control and Prevention’s 

(CDC) screening grant program authority 

to Lincoln County Health Department 

(LCHD) in Libby, Montana. A serious 

public health problem has been 

identified in Lincoln County, Montana, 

as residents in this rural community 

have been adversely affected by the 

asbestos released from a vermiculite 

mine. The asbestos-related diseases in 

which Lincoln County residents have 

been diagnosed include asbestosis, lung 

cancer, mesothelioma, and others. The 

purpose of this demonstration grant 

would be to provide care management 

for Lincoln County residents with 

asbestos-related diseases. The grant will 

provide funds to support the 

coordination and payment of care for 

asbestos-related diseases among such 

entities as hospitals, clinics, specialty 

care providers, and others involved in 

the care and treatment of this service 

population. 

SUPPLEMENTARY INFORMATION: 

Intended Recipient of the Award: 

Lincoln County Health Department in 

Libby, Montana. 

Amount of the Award FY 2009: It is 

anticipated that up to $6,000,000 will be 

available from all sources for a 2-year 

project period from August 1, 2009— 

July 31, 2011. Of the $6,000,000, 

$2,000,000 will be available from CDC 

to support this effort. The remaining 

$4,000,000 will be awarded by HRSA’s 

Office of Rural Health Policy’s Rural 

Health Care Services Outreach Program, 

of which $2,000,000 will be provided 

the first year and an additional 

$2,000,000 will be provided the second 

year. Funding beyond the first year, 

however, is dependent on the 

availability of appropriated funds, 

grantee satisfactory performance, and a 

decision that continued funding is in 

the best interest of the Federal 

Government. 

Project Period: The project period for 

this grant is August 1, 2009, through 

July 31, 2011. 

Authority: This activity is funded 

under the authority of HRSA’s Rural 

Health Care Services Outreach Program, 

statutory authority Section 330A(e) of 

the Public Health Service Act, as 

amended (42 U.S.C. 254c(e)); and the 

CDC’s statutory authority Section 

317(k)(2) of the Public Health Service 

Act, as amended (42 U.S.C. 247b(k)(2)). 

The authority for the single source 

award is HHS Grants Policy Directive 

2.04, Awarding Grants. 

Catalogue of Federal Domestic 

Assistance Number: HRSA’s Rural 

Health Care Services Outreach Grant: 

93.912. CDC Screening Program: 93.161. 

Justification for Single Source 

Awards: Because of the serious public 

health problem in Lincoln County, 

Montana, and the prevalence of 

mstockstill on DSKH9S0YB1PROD with NOTICES

34768 Federal Register / Vol. 74, No. 136 / Friday, July 17, 2009 / Notices 

asbestos-related diseases among the 

residents, their health is at risk of being 

severely impaired by lack of essential 

screening and related medical 

treatment. Due to the urgency of the 

situation, HRSA cannot run a full or 

limited competition since this process 

would take approximately 290 days. 

LCHD has been identified as uniquely 

qualified for undertaking this activity. 

LCHD has the requisite administrative 

and medical infrastructure as well as 

prior experience with screening and 

coordinating treatment with other local 

health care providers. In addition, 

tracking of disease incidents is a 

necessary component of the award 

activity and LCHD has previously 

worked with the Montana Department 

of Public Health and Human Services in 

developing and maintaining their 

asbestos-related disease registry. LCHD 

is in a unique position to immediately 

undertake and coordinate the award 

activities necessary to address this 

urgent public health problem and in a 

manner minimizing adverse health 

outcomes that might otherwise result 

from an extended delay in providing 

such services. 

FOR FURTHER INFORMATION CONTACT: Tom 

Morris, Associate Administrator, Office 

of Rural Health Policy, Health Resources 

and Services Administration, 5600 

Fishers Lane, Rockville, MD 20857; 

phone 301–443–0835; tmorris@hrsa.gov. 

Dated: July 10, 2009. 

Mary K. Wakefield, 

Administrator. 

[FR Doc. E9–16959 Filed 7–16–09; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID: FEMA–2009–0001] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice; 30-day notice and 

request for comments; new information 

collection; OMB No. 1660–NW35; 

FEMA Form 528–1, NEFRLS 

Registration; and FEMA Form 528–2, 

NEFRLS Search. 

SUMMARY: The Federal Emergency 

Management Agency (FEMA) has 

submitted the information collection 

abstracted below to the Office of 

Management and Budget for review and 

clearance in accordance with the 

requirements of the Paperwork 

Reduction Act of 1995. The submission 

describes the nature of the information 

collection, the categories of 

respondents, the estimated burden (i.e., 

the time, effort and resources used by 

respondents to respond) and cost, and 

includes the actual data collection 

instruments FEMA will use. 

DATES: Comments must be submitted on 

or before August 17, 2009. 

ADDRESSES: Submit written comments 

on the proposed information collection 

to the Office of Information and 

Regulatory Affairs, Office of 

Management and Budget. Comments 

should be addressed to the Desk Officer 

for the Department of Homeland 

Security, Federal Emergency 

Management Agency, and sent via 

electronic mail to 

oira.submission@omb.eop.gov or faxed 

to (202) 395–5806. 

FOR FURTHER INFORMATION CONTACT: 

Requests for additional information or 

copies of the information collection 

should be made to Director, Records 

Management Division, 1800 South Bell 

Street, Arlington, VA 20598–3005, 

facsimile number (202) 646–3347, or email address FEMA–InformationCollections@dhs.gov. 

SUPPLEMENTARY INFORMATION: 

Collection of Information 

Title: National Emergency Family 

Registry and Locator System (NEFRLS). 

Type of information collection: New 

information collection. 

OMB Number: 1660–NW35. 

Form Titles and Numbers: FEMA 

Form 528–1, NEFRLS Registration; and 

FEMA Form 528–2, NEFRLS Search. 

Abstract: NEFRLS is a Web-based 

system. The information collected in the 

NEFRLS will be used to help facilitate 

the reunification of family members that 

have been displaced due to a major 

disaster or emergency. 

Affected Public: Individuals or 

households. 

Estimated Number of Respondents: 

446,648. 

Frequency of Response: On Occasion. 

Estimated Average Hour Burden per 

Respondent: .74 Hours. 

Estimated Total Annual Burden 

Hours: 328,366. 

Estimated Cost: There is no start-up, 

operational or other costs associated 

with this information collection. 

Dated: July 10, 2009. 

Larry Gray, 

Director, Records Management Division, 

Office of Management, Federal Emergency 

Management Agency, Department of 

Homeland Security. 

[FR Doc. E9–17068 Filed 7–16–09; 8:45 am] 

BILLING CODE 9111–23–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID: FEMA–2009–0001] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: Notice; 60-day notice and 

request for comments; revision of a 

currently approved information 

collection; OMB No. 1660–0085; No 

Form. 

SUMMARY: The Federal Emergency 

Management Agency, as part of its 

continuing effort to reduce paperwork 

and respondent burden, invites the 

general public and other Federal 

agencies to take this opportunity to 

comment on a proposed revision of a 

currently approved information 

collection. In accordance with the 

Paperwork Reduction Act of 1995, this 

Notice seeks comments concerning the 

Crisis Counseling Assistance and 

Training Program for Immediate 

Services which provides funding in 

response to a State’s request for crisis 

counseling services for a Presidentiallydeclared disaster. 

DATES: Comments must be submitted on 

or before September 15, 2009. 

ADDRESSES: To avoid duplicate 

submissions to the docket, please use 

only one of the following means to 

submit comments: 

(1) Online. Submit comments at 

http://www.regulations.gov under 

docket ID FEMA–2009–0001. Follow the 

instructions for submitting comments. 

(2) Mail. Submit written comments to 

Office of Chief Counsel, Regulation and 

Policy Team, DHS/FEMA, 500 C Street, 

SW., Room 835, WASH, DC 20472– 

3100. 

(3) Facsimile. Submit comments to 

(703) 483–2999. 

(4) E-mail. Submit comments to 

FEMA-POLICY@dhs.gov. Include docket 

ID FEMA–2009–0001 in the subject line. 

All submissions received must 

include the agency name and docket ID. 

Regardless of the method used for 

mstockstill on DSKH9S0YB1PROD with NOTICES